CYTK logo

Cytokinetics Inc.

CYTK

CYTK: Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

more

Show CYTK Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CYTK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CYTK's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Tetrahydroisoquinoline derivatives Oct. 25, 2022
  • Patent Title: Cardiac sarcomere inhibitors Oct. 18, 2022
  • Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Oct. 18, 2022
  • Patent Title: Salts and crystal forms of omecamtiv mecarbil Oct. 11, 2022
  • Patent Title: Cardiac sarcomere inhibitors Aug. 16, 2022
  • Patent Title: Heterocyclic compounds and their uses Jul. 12, 2022
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Jun. 28, 2022
  • Patent Title: Bisamide sarcomere activating compounds and uses thereof Apr. 12, 2022
  • Patent Title: Process for the preparation of an amino-pyrimidine and intermediates thereof Oct. 12, 2021
  • Patent Title: Compounds, compositions and methods Apr. 13, 2021
  • Patent Title: Cardiac sarcomere inhibitors Nov. 17, 2020
  • Patent Title: Methods for preparing substituted imidazo[4,5-b]pyrazines Sep. 08, 2020
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Sep. 08, 2020
  • Patent Title: Compounds, compositions and methods Aug. 20, 2019
  • Patent Title: Combination als therapy Apr. 30, 2019
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Apr. 30, 2019
  • Patent Title: Substituted pyridazines as skeletal muscle modulators Sep. 18, 2018
  • Patent Title: Compounds, compositions and methods Jul. 31, 2018
  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Jun. 12, 2018
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Aug. 15, 2017
  • Patent Title: Substituted pyridazines as skeletal muscle modulators Mar. 28, 2017
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Mar. 08, 2016
  • Patent Title: Compounds, compositions and methods Oct. 06, 2015
  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Sep. 15, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Apr. 28, 2015
  • Patent Title: Amino-pyridazine skeletal muscle modulators Mar. 03, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Feb. 24, 2015
  • Patent Title: Certain chemical entities, compositions, and methods Nov. 25, 2014
  • Patent Title: Ureas and their use in the treatment of heart failure Oct. 28, 2014
  • Patent Title: Certain chemical entities, compositions and methods Oct. 28, 2014
  • Patent Title: Imidazole-benzamide anti-cancer agents Jul. 08, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Jun. 24, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Jun. 24, 2014
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use May. 06, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Apr. 01, 2014
  • Patent Title: Methods and compositions utilizing quinazolinones Feb. 25, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Feb. 18, 2014
  • Patent Title: Compounds, compositions and methods Jan. 21, 2014
  • Patent Title: Heterocyclic sulfonamides Dec. 10, 2013
  • Patent Title: Ureas and their use in the treatment of heart failure Aug. 20, 2013
  • Patent Title: Methods and compositions utilizing quinazolinones Jun. 25, 2013
  • Patent Title: Certain chemical entities, compositions and methods May. 21, 2013
  • Patent Title: Certain chemical entities, compositions and methods Apr. 02, 2013
  • Patent Title: Heterocyclic sulfonamides Feb. 05, 2013
  • Patent Title: Compounds, compositions and methods Dec. 11, 2012
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use Oct. 30, 2012
  • Patent Title: Certain chemical entities, compositions and methods Oct. 23, 2012
  • Patent Title: Modulating skeletal muscle Jul. 24, 2012
  • Patent Title: Imidazopyridinyl benzamide mitotic kinesin inhibitors Jun. 26, 2012
  • Patent Title: Heterocyclic sulfonamides Jun. 19, 2012
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CYTK in WallStreetBets Daily Discussion

CYTK News

Recent insights relating to CYTK

CNBC Recommendations

Recent picks made for CYTK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYTK

Corporate Flights

Flights by private jets registered to CYTK